search
Back to results

Pilot Study to Investigate the Effects of Increased Dialysate Magnesium and Dialysate Bicarbonate on the Calcification Propensity of Serum (BicMag)

Primary Purpose

End Stage Renal Failure on Dialysis, Vascular Calcification

Status
Completed
Phase
Not Applicable
Locations
Switzerland
Study Type
Interventional
Intervention
Magnesium
Bicarbonate
Sponsored by
Insel Gruppe AG, University Hospital Bern
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for End Stage Renal Failure on Dialysis

Eligibility Criteria

18 Years - 111 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Male or female hemodialysis patients ≥ 18 years of age
  • Negative pregnancy test of female patients in child-bearing age
  • The patients have to be able to understand the character and the individual impact of the clinical study and they have to give written informed consent to participate in the study
  • Start of chronic hemodialysis treatment ≥ 3 months ago
  • HCO3- in venous plasma ≤23 mmol/L before the start of the last dialysis of the week
  • Magnesium in venous plasma ≤ 1.45 mmol/L before the start of the first dialysis of the week
  • T50 ≥ 200 minutes.

Exclusion Criteria:

  • Pregnant or lactating subjects. A blood pregnancy test will be performed at the screening visit in female patients of childbearing age.
  • History of alcohol abuse, illicit drug use, significant mental illness, physical dependence to any opioid, or any history of drug abuse or addiction within 12 months of study enrolment

Sites / Locations

  • University Hospital Bern Inselspital

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Experimental

Arm Label

Mg first

Bicarbonate first

Arm Description

Receives MgCl2 first, MgCl2 and Bicarbonate in second phase

Receives Bicarbonate first, MgCl2 and Bicarbonate in second phase

Outcomes

Primary Outcome Measures

Effect of treatment on serum calcification propensity, measured by T50
T50: Transformation time of primary calciprotein particles to secondary calciprotein particles (Pasch et al, 2012)

Secondary Outcome Measures

Number of participants with treatment-related adverse events

Full Information

First Posted
November 26, 2015
Last Updated
September 25, 2017
Sponsor
Insel Gruppe AG, University Hospital Bern
search

1. Study Identification

Unique Protocol Identification Number
NCT02621762
Brief Title
Pilot Study to Investigate the Effects of Increased Dialysate Magnesium and Dialysate Bicarbonate on the Calcification Propensity of Serum
Acronym
BicMag
Official Title
Pilot Study to Investigate the Effects of Increased Dialysate Magnesium and Dialysate Bicarbonate on the Calcification Propensity of Serum
Study Type
Interventional

2. Study Status

Record Verification Date
September 2017
Overall Recruitment Status
Completed
Study Start Date
December 2015 (undefined)
Primary Completion Date
May 2016 (Actual)
Study Completion Date
May 2016 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Insel Gruppe AG, University Hospital Bern

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The study aims to determine the effect size of magnesium and bicarbonate supplementation as a basis for future randomized controlled trials aiming at the T50-guided improvement of hard clinical endpoints in dialysis patients.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
End Stage Renal Failure on Dialysis, Vascular Calcification

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Participant
Allocation
Non-Randomized
Enrollment
12 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Mg first
Arm Type
Experimental
Arm Description
Receives MgCl2 first, MgCl2 and Bicarbonate in second phase
Arm Title
Bicarbonate first
Arm Type
Experimental
Arm Description
Receives Bicarbonate first, MgCl2 and Bicarbonate in second phase
Intervention Type
Device
Intervention Name(s)
Magnesium
Intervention Description
Magnesium in dialysate increased
Intervention Type
Device
Intervention Name(s)
Bicarbonate
Intervention Description
Bicarbonate in dialysate increased
Primary Outcome Measure Information:
Title
Effect of treatment on serum calcification propensity, measured by T50
Description
T50: Transformation time of primary calciprotein particles to secondary calciprotein particles (Pasch et al, 2012)
Time Frame
7 weeks
Secondary Outcome Measure Information:
Title
Number of participants with treatment-related adverse events
Time Frame
7 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
111 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Male or female hemodialysis patients ≥ 18 years of age Negative pregnancy test of female patients in child-bearing age The patients have to be able to understand the character and the individual impact of the clinical study and they have to give written informed consent to participate in the study Start of chronic hemodialysis treatment ≥ 3 months ago HCO3- in venous plasma ≤23 mmol/L before the start of the last dialysis of the week Magnesium in venous plasma ≤ 1.45 mmol/L before the start of the first dialysis of the week T50 ≥ 200 minutes. Exclusion Criteria: Pregnant or lactating subjects. A blood pregnancy test will be performed at the screening visit in female patients of childbearing age. History of alcohol abuse, illicit drug use, significant mental illness, physical dependence to any opioid, or any history of drug abuse or addiction within 12 months of study enrolment
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Dominik Uehlinger, Prof Dr.med.
Organizational Affiliation
Insel Gruppe AG, University Hospital Bern
Official's Role
Principal Investigator
Facility Information:
Facility Name
University Hospital Bern Inselspital
City
Bern
State/Province
BE
ZIP/Postal Code
3008
Country
Switzerland

12. IPD Sharing Statement

Citations:
PubMed Identifier
22956818
Citation
Pasch A, Farese S, Graber S, Wald J, Richtering W, Floege J, Jahnen-Dechent W. Nanoparticle-based test measures overall propensity for calcification in serum. J Am Soc Nephrol. 2012 Oct;23(10):1744-52. doi: 10.1681/ASN.2012030240. Epub 2012 Sep 6.
Results Reference
background

Learn more about this trial

Pilot Study to Investigate the Effects of Increased Dialysate Magnesium and Dialysate Bicarbonate on the Calcification Propensity of Serum

We'll reach out to this number within 24 hrs